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Abstract Despite extensive use of immunohistochemistry
(IHC) for decades, lack of standardization remains a major
problem, even aggravated in the era of targeted therapy.
Nordic Immunohistochemical Quality Control (NordiQC) is
an international academic proficiency testing (PT) program
established in 2003 primarily aimed at assessing the analytical
phases of the laboratory IHC quality. About 700 laboratories
from 80 countries are currently participating. More than 30,
000 IHC slides have been evaluated during 2003–2015.
Overall, about 20 % of the staining results in the breast cancer
IHC module and about 30 % in the general module have been
assessed as insufficient for diagnostic use. The most common
causes for insufficient results are less successful antibodies
(poor and less robust antibodies, poorly calibrated ready-to-
use (RTU) products, and stainer platform-dependent antibod-
ies; 17 %), insufficiently calibrated antibody dilutions (20 %),
insufficient or erroneous epitope retrieval (27 %), less sensi-
tive visualization systems (19 %), and other (heat- and
proteolysis-induced impaired morphology, endogenous biotin
reaction, drying out phenomena, stainer platform-dependant
protocol issues; 17 %). Approximately, 90 % of the insuffi-
cient results are characterized by either a too weak or false
negative staining, whereas in the remaining 10 %, a poor
signal-to-noise ratio or false positive staining is seen.
Individually tailored recommendations for protocol optimiza-
tion and identification of best tissue controls to ensure
appropriate calibration of the IHC assay have for many
markers improved IHC staining as well as inter-laboratory
consistency of the IHC results. RTUs will not always provide
an optimal result and data sheets frequently misguide the lab-
oratories hampering the improvement in IHC quality. The
overall data generated by NordiQC during 12 years indicates
that continuous PT is valuable and necessary. Detailed de-
scription of the results of the NordiQC programme is available
on www.nordiqc.org and summarized in this paper.
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Introduction
Immunohistochemistry is technically complex, and no aspect
of this complexity can be ignored, from the moment of
collecting the specimen to issuance of the final report [1].
During the last four decades in pathology, immunohisto-
chemistry (IHC) has developed into an indispensable ancillary
diagnostic tool (class I assay), particularly in the classification
of neoplastic lesions. In the era of targeted cancer therapy, IHC
has also become a companion diagnostic (class II assay).
However, while the potential of IHC in pathology is univer-
sally accepted, it is still considered a “special stain” developed
in the individual laboratory rather than a tissue-based qualita-
tive or quantitative immunoassay, and its reliability is compro-
mised by lack of standardization, causing a high risk of sub-
optimal laboratory performance which leads to inferior pathol-
ogy diagnostics.
The “total test approach,” including standardization of the
preanalytical, analytical, and postanalytical processes, is of
outmost importance to ensure the technical, diagnostic, and
clinical quality of IHC. Nevertheless, numerous steps in the
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tissue processing and staining protocol are still defined by the
individual laboratory, the selection of tissue controls is largely
unregulated, and the interpretation of the staining results part-
ly subjective. Internal quality control is focused on the consis-
tency of the IHC assays, but does generally not give informa-
tion about the technical or diagnostic quality, and insufficient
assays often pass unnoticed through the laboratory validation
because of improper control tissues or lack of knowledge
about reaction patterns.
In selected areas, recommendations for standardization of
class II assays have been published by working groups and ad
hoc committees [2–5]. While these are helpful, many issues
remain. In particular, the identification of the best antibodies
and protocols for the IHC assays is still a challenge for the
individual laboratory. For each epitope to be demonstrated,
numerous parameters influence the sensitivity and specificity
of the assay. Even though meticulous and methodological
technical calibration of the IHC assays might be performed
in the laboratory, and a comprehensive quality control system
might exist to monitor the consistency of the assay, it is
still difficult to evaluate whether the IHC results are at
the level expected and comparable to that obtained by
other laboratories.
In IHC, proficiency testing (PT) or external quality as-
surance (EQA) is a method primarily aimed at the analyt-
ical outcome, i.e., the staining results, based on circulation
of serial sections of multi tissue arrays (TMAs) of “stan-
dard processed” tissues to be stained for defined proteins
in a large number of laboratories and assessed by a group
of experienced pathologists and biomedical scientists. The
principal advantage of EQA is the ability to detect differ-
ences of staining quality and relate these to the antibodies,
protocol parameters, and stainer platforms in order to iden-
tify which elements may give sufficient or insufficient
staining results. Thus, EQA can provide guidance on
how to achieve the best IHC standards. Guidance may
be given directly to the participants and used in publica-
tions on websites and in scientific journals.
The aim of the present paper is to give a short description of
the Nordic immunohistochemical Quality Control (NordiQC)
PT scheme.
Material and methods
In 1999, pathologists from Denmark, Finland, Norway, and
Sweden constructed a Nordic pilot scheme for EQA, and by
1st of January 2003, NordiQC was established as an academic
PT programme at the Institute of Pathology, Aalborg
University Hospital, Aalborg, Denmark. In the first annual
scheme, about 70 Nordic laboratories participated. Hereafter,
the programme was opened for other countries, and by 2015,
more than 700 laboratories from about 80 countries are
enrolled. Detailed description of the organization is available
on www.nordiqc.org and summarized below.
The NordiQC EQA scheme consists of three mod-
ules: (1) general module that includes tests for the most
common epitopes demonstrated in surgical and clinical
pathology to identify and subclassify neoplasms being
performed in three runs per year, each comprising 5–6
tests; (2) breast cancer IHC module that includes tests
for HER2, hormone receptors, and other markers rele-
vant in breast cancer pathology being performed in two
runs per year; and (3) breast cancer HER2 in situ hy-
bridization (ISH) module, also in two runs per year.
Slides of TMAs from standard processed formalin-fixed,
paraffin-embedded (FFPE) material are used for all
tests. For the breast cancer module and HER2 ISH
module, the tissues have been fixed and processed ac-
cording to the recommendations of the American
Society of Clinical Oncology/College of American
Pathologists (ASCP/CAP) and ad hoc committees for
IHC standardization [2–5]. The TMAs for each epitope
typically include 5–6 tissue cores of 4 mm from rele-
vant normal and neoplastic tissues expressing (whenever
possible) high, intermediate, and low levels of the epi-
tope to be tested, as well as tissue without epitope ex-
pression, in order to evaluate both the level of sensitiv-
ity and specificity of the assays. Normal tissues are
included to provide essential information about the op-
timal staining patterns that may allow them to be used
by the laboratories as reliable tissue controls. All tissues
are evaluated for the target epitope both before and after
the TMA construction to ensure that the levels of
Table 1 NordiQC scoring criteria. Consensus scoring of circulated
TMA slides in the assessor board based on the staining quality, i.e.,
staining intensity in cells expected to be demonstrated, signal-to-noise
ratio, background staining, aberrant staining pattern, counterstaining,
and preservation of morphology
Score Criteria
Optimal Staining reaction considered perfect or close to
perfect in all of the included tissue cores.
Good Staining reaction considered fully acceptable in all
of the included tissue cores. However, the
protocol may be optimized to ensure the best
staining intensity and signal-to-noise ratio.
Borderline Staining considered insufficient because of, e.g.,
a generally too weak staining or a false negative
staining of one of the included tissues, or a
minor false positive staining reaction.
Poor Staining considered very insufficient because
of, e.g., false negative staining of several of the
included tissues, or a major false positive
staining reaction.
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expression are as expected. Serial 3–4 μm sections are cut,
and for each TMA, the target epitope is evaluated in the
first, middle, and last section to monitor its expression
throughout the tissue. Participants enroll by completing a
web-based questionnaire that details about 50 analytical
variables regarding antibody, protocol, and platform used
for each of the epitopes to be demonstrated. For all tests,
two unstained slides are circulated to each of the attending
laboratories. The returned stained slides are assessed using
a traditional expert panel-based qualitative assessment sys-
tem. Each staining is evaluated by consensus as optimal,
good, borderline, or poor (Table 1). The staining results
are correlated to the data submitted by the participants in
order to identify variables important to the staining reac-
tions. The general staining results and results of the data
analysis are posted on www.nordiqc.org together with
information about the required staining patterns of tissues
included in the TMAs. Examples of antibodies, protocols,
and platforms giving optimal results are also posted.
Individual assessment scores are communicated directly
by e-mail to the participating laboratories. In case of an
insufficient result, tailored recommendations for improve-
ment are given. Reassessments may be requested based on
staining of new slides. The impact of recommendations in
case of insufficient stains is evaluated based on individual
reassessments and repeated challenges for the same
epitope.
Results
Detailed description of the NordiQC results is available on
www.nordiqc.org and summarized with examples below.
During January 2003–July 2015, 37 assessment runs have
been performed in the general IHC module, and 18 in the
breast cancer IHC module. Overall, challenges for 89 IHC
Table 2 IHC markers included in NordiQC runs 2003–2015
Alpha-methylacyl-CoA racemase (AMACR) CyclinD1 (CyD1) MLH1
Alpha-smooth muscle actin (ASMA) Cytokeratin (CK) 5 MSH2







Multiple myeloma oncogene 1 (MUM1)
Myosin, smooth muscle heavy chain (SMHCM)
B cell specific activator protein (BSAP, Pax5) CK, high molecular weight Napsin A
bcl-2protein CK, low molecular weight Neurofilament protein (NFP)
bcl-6protein CK, pan- Octamer transcription factor-3/4 (OCT3/4)
Calretinin Desmin p16ink4a
Cancer antigen 125 (CA125) Detected on GIST-1 (DOG1, anoctamin-1) p40
Carcinoembryonic antigen (CEA) E-cadherin p53
CD3 Epithelial cell adhesion molecule (EpCAM) p57
CD4 Epithelial membrane antigen (EMA) p63
CD5 Estrogen receptor alpha (ER) Paired box gene-2 protein (PAX2)
CD8 Factor VIII related antigen Paired box gene-8 protein (PAX8)
CD10 GATA3 Placental alkaline phosphatase (PLAP)
CD14 Glial fibrillary acidic protein (GFAP) PMS2
CD15 Glypican 3 Podoplanin










CD31 Hepatocyte antigen (HEPPAR1) S-100 protein beta
CD34 Human chorionic gonadotropin (HCG) Sal-like protein 4 (SALL4)
CD45 Immunoglobulin kappa (IgK) SOX10
CD56 Immunoglobulin lambda (IgL) Synaptophysin







Melanosoma specific antigen (MSA, HMB45)
Wilm’s tumor-1 protein (WT1)
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epitopes have been performed up to 16 times (Table 2).
Furthermore, seven runs have been performed in the HER2
ISH module (not included in this paper). The total number of
IHC slides assessed exceeds 30,000.
In the breast cancer IHC module, around 20 % of all stains
assessed by NordiQC have been marked insufficient, i.e., bor-
derline or poor, while in the general module, the proportion of
insufficient stains is around 30% (Fig. 1). In the largemajority
of about 9000 insufficient assays, the major cause has been
identified (Table 3). About 90 % of the insufficient stains are
characterized by a too weak or even false negative staining
reaction in one or more cores, while the remaining are insuf-
ficient due to poor signal-to-noise ratio, false positive, or com-
bined false negative and false positive.
Tests for estrogen receptor (ER) have been included in 14
runs during 2003–2015. During this period, the proportion of
sufficient stains has increased from 45 % in the first run to
about 70–90 % in the later runs (Fig. 2), tending to decrease
each time a larger group of laboratories participate for the first
time. In line with this observation, the pass rate has for “old”
participants consistently been higher than for the new ones, in
the latest run 73 vs. 51 %. During the same period, marked
improvements in the standardization and sensitivity of the pro-
tocols for ER have been recorded (see Table 4). Examples of
optimal and insufficient ER stains are illustrated in Fig. 3.
In tests for HER2 IHC, included in 19 runs during 2005–15,
the US Food and Drug Administration (FDA) approved kits
gave sufficient results in a high proportion throughout the period,
close to 90% in the latest runs. In contrast, laboratory-developed
assays most often gave poor results in the first runs and slowly
improved but is still below the level of the FDA and Conformité
Européene (CE) in vitro diagnostics (IVD) approved (Fig. 4).
However, also variation of the pass-rates between different
FDA-approved kits has been demonstrated. Examples of optimal
and insufficient HER2 stains are illustrated in Fig. 5.
In the general module, PT for almost 90 IHC markers
shows amore complex pattern. Improvements were often seen
for tests where the laboratories adjusted their protocols ac-
cording to tailored NordiQC recommendations. Thus, during
2003–2006, challenges for six epitopes (Chromogranin A,
Calretinin, CD5, CD15, CD23, and Cytokeratin low molecu-
lar weight) were performed three times. A total of 352 labo-
ratories that obtained an insufficient result for one of these
tests received specific guidelines on how to improve the per-
formance and participated in a subsequent run. Of the 352
laboratories, 227 (64 %) modified their protocols for the fol-
lowing test for the same epitope, of which a sufficient result
was obtained by 167 laboratories (74 %). The remaining 125
laboratories (36 %) did not modify their protocol. Of these,







































Fig. 2 Proportion of sufficient estrogen receptor test results in 14 runs
(full line) and number of laboratories participating in the challenges
(dotted line)
Table 3 Major causes of insufficient staining reactions
1. Less successful antibodies (17 %)
a. Poor antibodiesa
b. Less robust antibodiesb
c. Poorly calibrated RTUs
d. Stainer platform dependent antibodies
2. Insufficiently calibrated antibody dilutions (20 %)
3. Insufficient or erroneous epitope retrieval (27 %)
4. Error-prone or less sensitive visualization systemsc (19 %)
5 Other (17 %)
a. Heat-induced impaired morphology
b. Proteolysis induced impaired morphology
c. Drying out phenomena
d. Stainer platform-dependant protocol issues
e. Excessive counterstaining impairing interpretation
a Consistently gives false negative or false positive staining or a poor
signal-to-noise ratio in one or more assessment runs
b Frequently giving inferior staining results, e.g., due to mouse-anti-Golgi
reactions or sensitive to standard operations as blocking of endogenous
peroxidase
c Biotin-based detection kit for cytoplasmic epitopes, use of detection kits
providing a too low sensitivity, or use of detection kits and chromogens









Optimal Good Borderline Poor
%
General module Breast cancer IHC module
Fig. 1 Proportion of assessment scores applied to more than 20,000
assays in the general module and more than 9000 assays in the breast
cancer IHC module
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new test. Improvements have also been seen where the use of
poorest antibodies/clones have been reduced, typically be-
cause the participants have changed to new and better clones
and/or the companies have pruned them. This applies for, e.g.,
Synaptophysin (clone SY38), BSAP (Pax5) (clone 24), and
CD31 (clone 1A10) (Fig. 6).
In contrast little improvement has been realized for subop-
timal RTU systems. For example, in the NordiQC assessment
for CD45 (run 37, 2013), all protocols based on the RTU
system for the clone RP2/18 using the vendor recommended
protocol (which specifies omission of epitope retrieval) pro-
vided false negative results. In contrast, laboratories who
Fig. 3 Staining for estrogen receptor. a Optimal staining of uterine
cervix, which is recommended as positive control tissue. Note moderate
staining of the basal squamous epithelial cells, which are low expressors.
b Insufficient staining of the uterine cervix, the basal cells are negative.
This is typically caused by too low antibody titre antibody and/or
insufficient HIER. c Optimal staining of ductal breast carcinoma; most
nuclei are moderately positive. d Insufficient staining of same ductal
breast carcinoma as in (c), based on the same protocol as in (b), the
tumor is false negative. e Optimal staining of an estrogen receptor
negative ductal breast carcinoma obtained in all of 225 laboratories
using clone SP1, EP1, or 1D5, and 18 out of 37 laboratories using
clone 6F11. All neoplastic cells are negative while stromal cells are
positive, serving as internal control. f False positive staining reaction of
the same tumor as in (e) obtained in 15 out of 37 laboratories using clone
6F11. This (rare) staining reaction is possibly due to inadequate buffer
wash in combination with use of very sensitive protocol (×200)
Table 4 Increasing standardization in staining for estrogen receptor
among NordiQC participants
2003/2008 2015
Ready-to-use antibody/system 17 %a 66 %
Commercially available HIER buffer 12 %b 94 %
Alkaline HIER buffer 70 %b 94 %
Polymer/multimer-based detection kit 56 %b 93 %
Fully automated stainer platform 6 %b 59 %
a 2003
b 2008
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modified the vendor protocol by using HIER significantly
improved their results (Fig. 7). Also for tests where vendor
recommended protocols giving insufficient results conflict
with the NordiQC recommendations, the improvement has
often been disappointing. An example is the challenges for
Pan-Cytokeratin (Fig. 8).
Discussion
For many laboratories, calibration and validation of IHC as-
says for optimal performance remains a difficult task. The
implementation of IHC assays is complex, the test process
Fig. 5 Staining for HER2 protein. a–cOptimal staining of 3+ staining of
HER2 in gene-amplified ductal breast carcinoma (a), 2+ staining of
HER2 in gene-amplified ductal breast carcinoma (b), and 1+ staining of
HER2 in gene-unamplified ductal breast carcinoma (c). d–f Insufficient
(too weak staining) of the same tumors as in a–c, using a laboratory-
developed protocol: still a 3+ staining of the carcinoma in (d), but a 1+
staining of the carcinoma in (e) and 0 staining of the carcinoma in (f). g–i
Insufficient (too strong staining) of the same tumors as in a–c, using a
laboratory-developed protocol: strong 3+ staining in (g) and (h), false



























































Fig. 4 Proportion of sufficient HER2 IHC test results in 19 runs for FDA
approved and laboratory-developed assays (LDA). See text for details
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Fig. 6 Staining for CD31. aOptimal staining of normal liver, using clone
JC70A. Strong staining of the arterial endothelial cells and moderate
staining of sinusoidal endothelial cells is seen. b Insufficient staining of
the same liver as in (a) using clone 1A10. The sinusoidal endothelial cells
are false negative, while the arterial endothelial cells are still stained. In
three runs, 496 CD31 stained slides were assessed, of which 37 were
based on clone 1A10, all of which were insufficient. c Optimal staining
of angiosarcoma using clone JC70. d Insufficient staining of the same
tumor as in (c) using clone 1A10. The tumor is false negative. Only
normal endothelial cells with a high level of CD31 expression are
demonstrated (×200)
Fig. 7 Staining for CD45. a Normal liver showing optimal staining, the
Kupffer cells and vascular lymphocytes are strongly stained. b Same
tissue as in (a) giving false negative reaction in Kupffer cells with a low
level CD45 expression, due to omission of HIER (as recommended by the
vendor). c B cell chronic lymphatic leukemia optimally stained for CD45
with the same antibody as in (a). d Same tissue as in (c) giving false
negative reaction in the neoplastic cells, same protocol as in (b) (×200)
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gives an increased workload in the laboratory, and it requires a
high level of both technical and diagnostic expertise to inter-
pret the tests performed. This may be difficult to comply with
due to limited specialized IHC education and experience in the
laboratories. Efforts made to standardize and optimize IHC have
typically addressed general principles but not provided the spe-
cific data required to help laboratories to evaluate the technical
quality of the IHC assays used in routine diagnostics [6, 7].
Owing to the extensive requirements for laboratories to establish
technical optimization and validation, the use of RTU antibodies/
systems have for many markers gained popularity, but unfortu-
nately some RTU systems will not provide a sufficient result, as
shown by NordiQC. Participation in PT programmes provides
the laboratories with a tool to overcome some of these difficul-
ties. In addition to PT programmes, various time-limited ring
trials have been performed, e.g., a German nationwide PT of
breast cancer hormone receptors and HER2 assessment [8]. In
this trial, a significant improvement of performance was shown
for laboratories participating in more than one trial, which is in
line with the NordiQC experience. By publishing important re-
sults of the PT programmes and ring trials, all pathology labora-
tories are offered guidance to optimize their IHC protocols irre-
spective of participation in a specific programme [6].
Progress in performance for laboratories participating in PT
can be hard to evaluate properly. This is in part due to the
continuous increase in number of laboratories. Furthermore,
the assessment criteria may be adjusted (usually tightened)
according to new knowledge, more useful tissues included,
or rise of better antibodies and visualization systems, which
changes the conception of what is optimal.
Regardless of the cause(s) of insufficient staining results,
attention must be focused on the choice of tissue controls used
by the laboratory, the EQA programme, and the commercial
companies for calibration and validation of the IHC assays.
Identification of appropriate tissue controls is an ongoing pro-
cess. The international ad hoc committee [9, 10] has made
considerable contributions to determine the standards for tis-
sue controls to be used by pathology laboratories as well as
diagnostic companies developing IHC reagents and equip-
ment. The fact that about 90 % of the insufficient results in
the NordiQC PTassessments are characterized by too weak or
completely false negative staining reaction clearly indicates
that the main challenge to both laboratory-developed and
RTU assays is to perform a precise calibration, which can be
established only by selecting proper controls with known low
amounts of the target epitope [9, 10]. Only by identification
and accurate characterization of expected staining patterns in
well-defined tissue controls is it possible to evaluate reliably
the technical quality and to monitor the impact of changes of
analytical variables. For typical qualitative IHC assays, such
as CD31 (Fig. 6), CD45 (Fig. 7), Chromogranin A, CDX2,
and Cytokeratins (pan-, low, and high molecular weight), it
Fig. 8 Staining for Pan-cytokeratin (PCK), using clone cocktail AE1/
AE3. a Normal liver showing optimal staining: strong reaction in bile
ducts, moderate reaction in liver cells. b Insufficient staining of liver
(same tissue as in (a)): The liver cells are false negative, due to
proteolytic pretreatment (as recommended by the vendor of the primary
antibody) instead of HIER (as recommended by NordiQC). c Clear cell
renal cell carcinoma stained like in (a) showing strong membrane-related
staining. d The same tumor and approximately the same field as in (c),
same protocol as in (d) giving false negative reaction in the tumor (×200)
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has been shown in the NordiQC programme that precise in-
formation regarding the level of technical sensitivity can be
made only by interpretation of the staining reaction in tissues
with weak expression of the target epitope, whereas mislead-
ing conclusions can be made if only tissues with high expres-
sion levels are used. This is in line with the cIQc experience
[11, 12]. For CDX2, the NordiQC results have been confirmed
by comparing different CDX2 antibodies in a large cohort of
normal and neoplastic tissues [13]. Only by using pancreas as
a CDX2 tissue control and focusing on the ability to demon-
strate the small amount of CDX2 in cells of the ductal
epithelium can a reliable demonstration of CDX2 be made
in neoplasias with low expression levels.
Selection of sensitive antibodies and optimization of pro-
tocols to the best signal-to-noise ratio may in some cases ham-
per the “diagnostic specificity.” E.g., in lung cancer, reports
have found that thyroid transcription factor-1 (TTF-1) clone
8G7G3/1 was positive in 1 % of squamous cell carcinomas,
and 65–77 % of lung adenocarcinomas, whereas TTF-1 clone
SPT24 was positive in 17 % of squamous cell carcinomas and
72–84 % of adenocarcinomas [14]. In order to avoid the TTF-
1 staining of squamous cell carcinomas, WHO recommends
Fig. 9 Staining for TTF-1. a Poorly differentiated adenocarcinoma
(right) showing strong staining. A normal bronchus (top) showing
strong staining of basal cells and moderate staining of luminal cells.
The staining based on clone SPT24. Clone SP141 gives the same
reaction. b Same field as in (a) showing moderate staining of the tumor,
weak staining of the basal cells and negative reaction of the luminal cells.
The staining is based on clone 8G7G3/1 and a carefully calibrated
protocol to provide the best possible technical signal-to-noise ratio.
Clone MX011 gives the same sta ining react ion. c Lung
adenocarcinoma stained with the same antibody and protocol as in (a).
Moderate staining of all tumor cells. d Same field as in (c), same antibody
and protocol as in (b). The tumor is false negative. Normal pneumocytes
are stained. e Lung squamous cell carcinoma (which was strongly
positive for p40) stained with the same antibody and protocol as in (a).
Moderate staining of tumor cells. Note the strongly stained
pnenumocytes. f Same field as in (e) stained with the same antibody
and protocol as in (a). The tumor is negative for TTF-1 (few nuclei
equivocally positive). Note the pneumocytes stained only slightly
weaker than in (e) (×200)
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usage of clone 8G7G3/1 [15]. However, this recommendation
may conflict with the principle of optimizing staining reac-
tions to the best signal-to-noise ratio which include selection
of the most sensitive and specific clones and carefully cali-
brating the dilution on low expressing cells in normal tissues
(Fig. 9). Setting up appropriate antibody panels may be a
better alternative to the use of less sensitive antibodies or
suboptimal protocols which will impede standardization of
IHC.
Recently and looking toward the future, IHC will be pro-
viding a window onto the molecular alterations which under-
lie cancers. This has been designated as “Next generation
IHC” [16]. Due to genetic tumor changes, proteins may be
lost (e.g., mismatch repair proteins, E-cadherin, INI1), over-
expressed (e.g., p53, HER-2, bcl-2), or antigenically changed
(e.g., ALK, BRAF, IDH1), whichmay be revealed by IHC. As
these tests are “stand-alone” assays, they make high demands
on the IHC standardization.
In assays where semiquantitative analyses are to be carried
out (e.g., HER2, estrogen receptor protein, Ki67), the prob-
lems with inter- and intra-laboratory reproducibility may be
overcome by using digital image analysis (DIA) [17].
However, in order to introduce DIA in the diagnostic work,
standardization and EQA becomes even more important. DIA
can also be implemented in PT assessment to strengthen the
manual procedure. Thus, in a NordiQC study, DIA of HER-2
stained slides of breast cancers could be used to define precise
levels of membrane connectivity to distinguish between opti-
mal and suboptimal staining reactions, allowing for better cal-
ibration of the immunoassays [18].
IHC PT programmes based on expert panel-based qualita-
tive assessment systems, which work internationally and/or
publish their results in English, include United Kingdom
National External Quality Assessment Scheme for
Immunocytochemistry (UK NEQAS ICC), Canadian
Immunohistochemical Quality Control (cIQc), The Royal
College of Pathologists of Australasia, Quality Assurance
Programmes (RCPAQAP), and NordiQC. These programmes
use different approaches in evaluating the performance of in-
dividual participating laboratories but are all rooted in a com-
parative method in which a judgment is rendered by a panel of
expert assessors, striving to achieve consistency and accuracy
in the operation of clinical laboratories with the ultimate goal
of improved patient safety. The time has come for these and
other PT programmes to joining forces for common standards
in IHC. Initiatives have currently been taken to construct an
International Quality Network for Pathology (IQN Path,
www.iqnpath.org) aimed to delivering improved clinical
implementation of tissue-based biomarkers through multi-
stakeholder cooperation, exchange expertise between key
opinion leaders in the field, pool resources to quickly establish
recommendations for new biomarker adoption, establish
benchmarks and best practice, coordinate interaction between
international experts and different stakeholders involved in
quality assessment thereby supporting faster adoption of
new biomarkers and technology, and promote EQA/PT by
creating compelling evidence to inform and lead policy
development, identifying trends and emerging needs in
the field creating a stronger voice for EQA providers
(www.iqnpath.org).
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